Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

IPO Prophet® is a real-time IPO intelligence platform that gives investors a data-driven edge. Our team brings over 75 years of combined experience trading and investing in IPOs, translating firsthand market execution into proprietary quantitative analytics designed for today’s issuance environment.

Unlike traditional research providers that rely solely on commentary and retrospective analysis, IPO Prophet® is grounded in actual trading experience across multiple IPO cycles. Our platform integrates live market data, historical performance benchmarks, and predictive models to help investors evaluate deal quality, pricing discipline, demand strength, and post-IPO trading behavior as it unfolds.

From pre-deal analysis through pricing and aftermarket performance, IPO Prophet® delivers actionable, data-driven intelligence that helps investors make informed decisions at the moments that matter most.

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Bottom-Up

<ul>
<li>Braveheart Bio is expected to list on the Nasdaq under the ticker BRVE, offering 18.75 million shares at a price range of $15.00 to $17.00 per share, targeting approximately $300 million in gross proceeds.</li>
<li>The company is developing novel therapies for hypertrophic cardiomyopathy (HCM) and related cardiovascular diseases.</li>
<li>Its lead candidate, BHB-1893, is an oral cardiac myosin inhibitor designed to treat both obstructive and non-obstructive HCM, addressing a large specialty cardiovascular market with significant unmet need.</li>
</ul>


Braveheart Bio is expected to list on the Nasdaq under the ticker BRVE, offering 18.75 million shares at a price range of $15.00 to $17.00 per share, targeting approximately $300 million in gross proceeds.
The company is developing novel therapies for hypertrophic cardiomyopathy (HCM) and related cardiovascular diseases.
Its lead candidate, BHB-1893, is an oral cardiac myosin inhibitor designed to treat both obstructive and non-obstructive HCM, addressing a large specialty cardiovascular market with significant unmet need.


Braveheart Bio

IPO Rating: Braveheart Bio Inc. (BRVE)